The Genzyme deal: what's the hold-up?
This article was originally published in Scrip
With expectations running high that the final terms of the acquisition of Genzyme by Sanofi-Aventis would be announced with Sanofi’s quarterly results on Wednesday, the absence of not just the announcement, but any colour on the negotiations may be worrying to some investors.
You may also be interested in...
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.
It is one thing to aspire to build a rival to another company’s banner therapeutic franchise, but quite another to start from the ground up, especially when your form in that area is mixed.